Review Article
Volume 16 Issue 07 - 2020
Controlling COVID-19 in Humans
Italo M Cesari
Emeritus Senior Researcher, Laboratorio de Inmunoparasitología, Centro de Microbiología y Biología Celular, Instituto Venezolano de Investigaciones Científicas (IVIC), Caracas, Venezuela
*Corresponding Author: Italo M Cesari, Emeritus Senior Researcher, Laboratorio de Inmunoparasitología, Centro de Microbiología y Biología Celular, Instituto Venezolano de Investigaciones Científicas (IVIC), Caracas, Venezuela.
Received: March 27, 2020; Published: June 04, 2020




Abstract

The surprising pandemic of the respiratory syndrome disease COVID-19 caused by the new coronavirus SARS-CoV-2 has forced scientists, clinicians and/or health professionals to rapidly dedicate themselves to study with celerity and depth not only on the causes of the disease and pandemic but also how to address antiviral strategies, applying the best knowledge available to avoid contagion, decrease transmission, identify the subsequent phases of the infection, and avoid the most serious pathological consequences of this disease: respiratory and cardiovascular distress, multiorgan failure and death. On these bases, in the present work we wanted to review and to discuss on the CoV-host interactions, commenting possible ways to control COVID-19 in humans from the perspective of an integrated use of crossing strategies: sanitary control, direct antiviral treatment, use of antioxidants, anti-inflammatories and other agents, with micronutritional support of infected patients, as a challenging contribution to handling and control COVID-19 infections..

Keywords: SARS-CoV-2; COVID-19; Virus-Host Interactions; Antiviral Treatments; Disease Control Strategies

References

  1. Cascella M., et al. “Features, Evaluation and Treatment Coronavirus (COVID-19)”. StatPearls (2020).
  2. Wu A., et al. “Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China”. Cell Host and Microbe 27 (2020): 325-328.
  3. Wu J and Chow D. “Are coronavirus diseases equally deadly? Comparing the latest coronavirus to MERS and SARS” (2020).
  4. “WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) Report” (2019).
  5. Huang Y., et al. “Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China”. medRxiv (2020).
  6. Li Q., et al. “Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia”. The New England Journal of Medicine 13 (2020): 1199.
  7. Kikkert M. “Innate Immune Evasion by Human Respiratory RNA Viruses”. Journal of Innate Immunity1 (2020): 4-20.
  8. King A. “Possible Biological Explanations for Kids’ Escape from COVID-19” (2020).
  9. “WHO-Coronavirus disease (COVID-19) advice for the public” (2020).
  10. Kimura H., et al. “Cytokine production and signaling pathways in respiratory virus infection”. Frontiers in Microbiology 4 (2013): 276.
  11. Pedersen F and Ho Y-C. “SARS-CoV-2: A Storm Is Raging”. Journal of Clinical Investigations5 (2020): 2202-2205.
  12. Chen G., et al. “Clinical and immunologic features in severe and moderate forms of Coronavirus Disease 2019”. Clinical Investigations5 (2020): 2620-2629.
  13. Shi H., et al. “Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study”. The Lancet 20 (2020): 425.
  14. Jia HP., et al. “ACE2 Receptor Expression and Severe Acute Respiratory Syndrome Coronavirus Infection Depend on Differentiation of Human Airway Epithelia”. Journal of Virology23 (2005): 14614-14621.
  15. Wang M., et al. “Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro”. Cell Research 30 (2020): 269-271.
  16. Ahmed S., et al. “Honey as a Potential Natural Antioxidant Medicine: An Insight into Its Molecular Mechanisms of Action”. Oxidative Medicine and Cellular Longevity (2018): 8367846.
  17. Hoffman M., et al. “The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells”. bioRxiv (2020).
  18. Wu C., et al. “Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods”. Acta Pharmaceutica Sinica B (2020).
  19. Tikellis C and Thomas MC. “Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease”. International Journal of Peptides (2012): 256294.
  20. Oudit GY., et al. “The role of ACE2 in pulmonary diseases- relevance for the nephrologist”. Nephrology Dialysis Transplantation 5 (2009): 1362-1365.
  21. Kuba K., et al. “Multiple Functions of Angiotensin-Converting Enzyme 2 and Its Relevance in Cardiovascular Diseases”. Circulation Journal2 (2013): 301-308.
  22. Sparks MA., et al. "The Coronavirus Conundrum: ACE2 and Hypertension Edition”. Nephrology Journal Club (2020).
  23. Xiao HL., et al. “Association between ACE2/ACE balance and pneumocyte apoptosis in a porcine model of acute pulmonary thromboembolism with cardiac arrest”. Molecular Medicine Reports3 (2018): 4221-4228.
  24. Jia HP., et al. “ACE2 Receptor Expression and Severe Acute Respiratory Syndrome Coronavirus Infection Depend on Differentiation of Human Airway Epithelia”. Journal of Virology23 (2005): 14614-14621.
  25. Kuba K., et al. “A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury”. Nature Medicine8 (2005): 875-879.
  26. Chasmi-Pasha AR., et al. “Angiotensin-Converting Enzyme 2 as a Therapeutic Target for Heart Failure”. Current Heart Failure Reports1 (2014): 58-63.
  27. Hoffmann M., et al. “SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically-proven protease inhibitor”. Cell (2020).
  28. Ho TY., et al. “Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction”. Antiviral Research2 (2007): 92-101.
  29. Chen H and Du Q. “Potential natural compounds for preventing 2019-nCoV infection”. Preprints (2020): 2020010358.
  30. Li X., et al. “A furin cleavage site was discovered in the S protein of the 2019 novel coronavirus”. Chinese Journal of Bioinformatics 2 (2020): 1-4.
  31. Becker GL., et al. “Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics”. Journal of Medicinal Chemistry3 (2010): 1067-1075.
  32. Lei J., et al. “Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein”. Antiviral Research 149 (2018): 58-74.
  33. Blanchard JE., et al. “High-Throughput Screening Identifies Inhibitors of the SARS Coronavirus Main Proteinase”. Chemistry and Biology10 (2004): 1445-1453.
  34. Dayer MR., et al. “Lopinavir: A Potent Drug against Coronavirus Infection: Insight from Molecular Docking Study”. Archives of Clinical Infectious Diseases4 (2017): e13823.
  35. Ortega JT., et al. “Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target”. EXCLI Journal 19 (2020): 400-409.
  36. Liu X and Wang XJ. “Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines”. bioRxiv (2020).
  37. Park TY., et al. “Chloroquine modulates inflammatory autoimmune responses through Nurr1 in autoimmune diseases”. Scientific Reports 9 (2019): 15559.
  38. Savarino A., et al. “Effects of chloroquine on viral infections: an old drug against today’s diseases?” Lancet Infectious Diseases 11 (2003): 722-727.
  39. Gao J., et al. “Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies”. BioSciences Trends1 (2020): 72-73.
  40. Gautret P., et al. “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial”. International Journal of Antimicrobial Agents (2020).
  41. Ferrer-Mayorga G., et al. “Cystatin D Locates in the Nucleus at Sites of Active Transcription and Modulates Gene and Protein Expression”. Journal of Biological Chemistry 44 (2015): 26533-26548.
  42. Collins AR and Grubb A. “Cystatin D, a natural salivary cysteine protease inhibitor, inhibits coronavirus replication at its physiologic concentration”. Oral Microbiology and Immunology1 (1998): 59-61.
  43. Khaerunnisa S., et al. “Potential Inhibitor of COVID-19 Main Protease (Mpro) from Several Medicinal Plant Compounds by Molecular Docking Study”. Preprints (2020).
  44. Lin SC., et al. “Effective inhibition of MERS-CoV infection by resveratrol”. BMC Infectious Diseases 17 (2017): 144.
  45. Vincent MJ., et al. “Chloroquine is a potent inhibitor of SARS coronavirus infection and spread”. Virology Journal 2 (2005): 69.
  46. Nukoolkarn V., et al. “Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors”. Journal of Theoretical Biology4 (2008): 861-867.
  47. Li SY., et al. “Identification of natural compounds with antiviral activities against SARS-associated coronavirus”. Antiviral Research1 (2005): 18-23.
  48. Hosakote YM., et al. “Viral-mediated inhibition of antioxidant enzymes contributes to the pathogenesis of severe respiratory syncytial virus bronchiolitis”. American Journal of Respiratory and Critical Care Medicine11 (2011): 1550-1560.
  49. Lee C. “Therapeutic Modulation of Virus-Induced Oxidative Stress via the Nrf2-Dependent Antioxidative Pathway”. Oxidative Medicine and Cellular Longevity (2018): 6208067.
  50. Yang R., et al. “Enhancement of glucosinolate and sulforaphane formation of broccoli sprouts by zinc sulphate via its stress effect”. Journal of Functional Foods 13 (2015).
  51. Qi Q., et al. “Effect of N-acetylcysteine on exacerbations of bronchiectasis (BENE): a randomized controlled trial”. Respiratory Research 20 (2019): 73.
  52. Kang MY., et al. “The critical role of catalase in prooxidant and antioxidant function of p53”. Cell Death and Differentiation 20 (2013): 117-129.
  53. Echevarria-Lima J., et al. “The Role of Glutathione in Viral Diseases of the Central Nervous System”. Intechopen (2018).
  54. Sun Y., et al. “Preventive and protective roles of dietary Nrf2 activators against central nervous system diseases”. Dietary Components and Immune Function (2010): 421-468.
  55. Gullin OM., et al. “Selenium, Selenoproteins and Viral Infection”. Nutrients 9 (2019): 2101.
  56. Horvathova E., et al. “Assessment of antioxidative, chelating, and DNA-protective effects of selected essential oil components (eugenol, carvacrol, thymol, borneol, eucalyptol) of plants and intact Rosmarinus officinalis oil”. Journal of Agricultural and Food Chemistry62.28 (2014): 6632-6639.
  57. Kim HJ., et al. “Reactive Oxygen Species Induce Antiviral Innate Immune Response through IFN-λ Regulation in Human Nasal Epithelial Cells”. American Journal of Respiratory Cell and Molecular Biology5 (2013): 855-865.
  58. Khomich OA., et al. “Redox Biology of Respiratory Viral Infections”. Viruses 8 (2018): 392.
  59. Coperchini F., et al. “The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system”. Cytokine and Growth Factor Reviews (2020).
  60. Guan F., et al. “Majority of Chinese Medicine Herb Category “Qing Re Yao” Have Multiple Mechanisms of Antiinflammatory Activity”. Scientific Reports 8 (2018): 7416.
  61. Mima T and Nishimoto N. “Clinical value of blocking IL-6 receptor”. Current Opinions in Rheumatology3 (2009): 224-230.
  62. Michot JM., et al. “Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report”. Annals of Oncology (2020).
  63. Maroon JC., et al. “Natural anti-inflammatory agents for pain relief”. Surgical Neurology International 1 (2010): 80.
  64. Li Y., et al. “1, 8-Cineol Protect Against Influenza-Virus-Induced Pneumonia in Mice”. Inflammation 4 (2016): 1582-1593.
  65. Zhao C., et al. “1,8-cineol attenuates LPS-induced acute pulmonary inflammation in mice”. Inflammation 2 (2014): 566-572.
  66. Juergens UR. “Anti-inflammatory Properties of the Monoterpene 1.8-cineole: Current Evidence for Co-medication in Inflammatory Airway Diseases”. Drug Research 12 (2014): 638-646.
  67. He Y., et al. “Curcumin, Inflammation, and Chronic Diseases: How Are They Linked?”. Molecules5 (2015): 9183-9213.
  68. Moura FA., et al. “Lipoic Acid: its antioxidant and anti-inflammatory role and clinical applications”. Current Topics in Medicinal Chemistry5 (2015): 458-483.
  69. Culpitt SV., et al. “Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD”. Thorax11 (2003): 942-946.
  70. Kindler E., et al. “Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response”. Advances in Virus Research 96 (2016): 219-243.
  71. Adams C. “Lectins Fight Viruses, Low Levels linked to Diseases” (2014).
  72. Zhou Y., et al. “A Single Asparagine-Linked Glycosylation Site of the Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Facilitates Inhibition by Mannose-Binding Lectin through Multiple Mechanisms”. Journal of Virology17 (2010): 8753-8764.
  73. Zhang W., et al. “Chicken mannose binding lectin has antiviral activity towards infectious bronchitis virus”. Virology 509 (2017): 252-259.
  74. Eisen DP. “Mannose-Binding Lectin Deficiency and Respiratory Tract Infection”. Journal of Innate Immunity 2 (2010): 114-122.
  75. Grant WB., et al. “Evidence That Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths”. Nutrients4 (2020): E988.
Citation: Italo M Cesari. “Controlling COVID-19 in Humans”. EC Microbiology 16.7 (2020): 19-31.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


March Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the March issue of respective journals and can be viewed in the current issue pages.

Submission Deadline for April Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the April issue of respective journals. Submissions are accepted on/before March 22, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk